Site Map
Powerful Efficacy
- Study Design
- Clinical Trial Results
- Post Hoc Analysis
Powerful Efficacy
Demonstrated Safety Profile
- Safety and Tolerability
- KESIMPTA and Vaccines
Demonstrated Safety Profile
Access & Resources
Skip to main content
IMPORTANT SAFETY INFORMATION
Contraindications: KESIMPTA is contraindicated in patients with active hepatitis B virus (HBV) infection, or history of hypersensitivity to ofatumumab, or life-threatening injection-related reaction to KESIMPTA. Hypersensitivity reactions have included anaphylaxis and angioedema.
Warnings and Precautions
Infections: Serious, including life-threatening or fatal, bacterial, fungal, and new or reactivated viral infections have been observed during and following completion of treatment with anti-CD20 B-cell depleting therapies....
INDICATION
KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults...
Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION